The products of the company are intended for cardiovascular diseases, metabolism issues, fibrosis, immune-related diseases, HCV and cancer. As a leader in microRNA therapeutics, they have over 900 patents and patent applications. Of this number, approximately 600 are involved in the method of application, modification of chemicals and administration of oligonucleotides to specific targets. To further enhance their leadership in this field of therapeutics, the company has partnered with over 30 academic research laboratories around the world. World class scientists also sit as part of their scientific advisory board together with foremost authorities in this field of specialization.
Headquartered in La Jolla, California, the company employs a very small number of associates. With only 54 employees, the business remains a leader in microRNA research and development. Common stocks of the company are traded publicly on the NASDAQ.